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Introduction 
Methotrexate (MTX) and 6-thioguanine (6-TG) are antimetabolites used both 
singly and in combination for the treatment of various forms of leukemia and other 
neoplasms (1,2). The mechanism of action of MTX has been extensively 
investigated. By inhibition of the cellular enzyme, dihydrofolate reductase, MTX 
causes a depletion of reduced folates which are necessary for a number of 
biosynthetic reactions including de novo purine and thymidylic acid synthesis (1); 
Figure 1 illustrates this effect. In the cell this depletion of the thymidine and 
purine deoxynucleotides leads to suppression of DNA synthesis and ultimately to 
cell death. If cells are provided with an exogenous source of purines such as 
inosine or hypoxanthine and with exogenous thymidine, the cytotoxicity of MTX is 
circumvented. Another indirect metabolic consequence of MTX treatment is an 
increase in the intracellular concentration of phosphoribosylpyrophosphate (PRPP) 
due to the suppression of purine biosynthesis. By itself, the expansion of PRPP 
pools is of little consequence, but it can increase the rate of metabolism of other 
molecules which utilize PRPP as a cofactor. In the case of 5-fluorouracil (FUra), a 
cytotoxic agent which is activated by conversion of FUra to FUra-ribosephosphate 
using PRPP and ©rotate phosphoribosyltransferase, it has been shown that 
pretreatment of cells with MTX leads to increased activation of FUra and 
enhanced cytotoxicity (3,4). Thus MTX treatment, in addition to its inherent 
toxicity, can metabolically increase the effectiveness of certain other agents 
leading to synergistic cytotoxicity. 
The mechanism of 6-TG toxicity is much less well established. It is 
converted in the cell to 6-TG ribosephosphate (6-TGRP) by the enzyme 
hypoxanthine-guanine phosphoribosyltransferase using PRPP as the cofactor; this 
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conversion is apparently necessary for the cytotoxic action of 6-TG. While 
6-TGRP has been shown to inhibit a number of enzymes involved in purine 
biosynthesis, it has been reported that the primary mechanism of cytotoxicity of 
6-TG is via its incorporation into DNA (5). Incorporation of 6-TG into RNA has 
been reported, but no connection between this incorporation and cell toxicity has 
been shown. Since 6-TG, like FUra, is activated by reacting with PRPP(1,2), it 
seemed possible that 6-TG and MTX might have a synergistic interaction analogous 
to that already demonstrated between MTX and FUra. 
The present study characterizes cytotoxic and metabolic interactions 
between MTX and 6-TG in L1210 mouse leukemia cells in culture. It is shown that 
there is indeed a modulation of 6-TG activity by MTX. 
Materials and Methods 
Chemicals. (^C)6-TG was purchased from Moravek Biochemicals (City of 
Industry, CA). MTX was purchased from Lederle Laboratories (Wayne, NJ). All 
other biochemicals were obtained from Sigma Chemical Co. (St. Louis, MO). 
Tissue culture supplies (unless otherwise designated) were obtained from Gibco 
Laboratories (Grand Island, NY). 
Cells. L1210 murine leukemia cells were maintained in suspension culture with 
Fischer's medium supplemented with 10% heat-inactivated horse serum at 37°C in 
a 5% CO2 atmosphere. All experiments were performed using logarithmically 
growing cells (1 to 5 x 10^ cells/ml) which had been initially seeded at 1 to 3 x 10^ 
cells/ml. Cell density was determined with the use of a model ZBI Coulter Counter 
(Coulter Electronics, Hialeah, FL). 
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Cloning. Cell viability and drug toxicity were determined using the soft-agar 
cloning assay as described by Cadman et al. (3). Following the indicated single 
drug exposure to logarithmically growing cell cultures, the second drug was added 
for the specified time. The drug-containing medium was then removed after 
centrifugation at 1000 x g for 5 min at 37°C. The cells were resuspended in 
drug-free medium and recentrifuged as before. This washing procedure was 
repeated twice to remove any extracellular drug before cloning. Fifty cells 
contained in 2 ml of liquified agar 37°C and 3 ml of drug-free Fischer's medium 
plus 15% horse serum were pipetted into 10 ml culture tubes. The tubes were 
capped, placed in an upright position and incubated at 37°C in a 5% CC>2 
atmosphere. The amount of agar in the culture medium was 88 mg/100 ml; the 
consistency of this mixture allows cell growth without cell settling. Cells that 
remain viable after drug exposure, as defined by the capability to divide and 
produce progeny, will form individual cell colonies after 10 days of incubation. All 
clones were counted with an inverted microscope. Single cells, which can be 
visualized in suspension cultures were not observed in the cloning medium after the 
10 day incubation, indicating that all viable cells had developed into clones. The 
percent viability is the ratio of clones formed from drug-treated cultures to clones 
formed from untreated cultures, multiplied by 100. The cloning efficiency of 
L1210 cells in this system was 85 to 90%, All data shown are the mean of 
triplicate experiments performed on 3 separate occasions. The variation between 
experiments was less than 10%. Drug concentrations were measured by 
spectrophotometric analysis and drug solutions were prepared the same day of use. 
6-TG Metabolism. Cells were exposed to (^C)6-TG for time periods from 1 to 
180 min. At the specified time, iced saline containing 50 jjM dipyridamole was 
added; the cell pellet was immediately isolated by centrifugation and then 
disrupted by the addition of ice-cold 0.2 N HCIO^. To a tube which contained the 
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iced cells (^C)6-TG was added as a control to determine the amount of 
non-specific radioactivity that would persist during the following DNA and RNA 
isolation procedures. The acid-soluble fraction was isolated for HPLC analysis of 
intracellular 6-TG nucleotides. The RNA and DNA were isolated from the 
acid-precipitate as follows: The acid-precipitate was washed twice with iced 
0.2 N HCIO^, followed by the addition of 3 ml of 0.3 N NaOH to the washed pellet. 
The precipitate was then digested for 1 hour at 37°C. After cooling on ice, DNA 
and protein were precipitated by the addition of 300 pi 5.2 N HCIO^. Five hundred 
microliters of the isolated supernatant (containing the RNA fraction) was measured 
or radioactivity. This process was repeated twice to insure complete removal of 
all RNA from the remaining precipitate. Following removal of the RNA-containing 
supernatant, the precipitate was washed twice with iced 0.2 N HCIO^, resuspended 
in 3 ml of 0.5 N HCIO^, and incubated at 70°C for 30 min to solubilize the DNA 
fraction. After cooling on ice, the sample was centrifuged and 500 pM of the 
supernatant (containing the DNA fraction) was measured for radioactivity. The 
precipitate was then washed twice with 0.5 N HCIO^ and digested for 1 hour at 
70°C in 3 ml of 0.5 N KOH. Five hundred microliters of the supernatant 
(containing the protein fraction) was neutralized with 1 N HC1 and measured for 
radioactivity. Total RNA was quantitated by the orcinol reaction, and total DNA 
was quantitated by a standard diphenylamine procedure (6). HPLC analysis of acid- 
soluble pools was carried out on a SAX anion-exchange column using a 60 min 
linear gradient from 0.01 M potassium phosphate (pH 5.7) to 0.75 M potassium 
phosphate (pH 4.7). 
Cesium Sulfate Gradients. Incorporation of (^C)6-TG into nucleic acid was 
studied using the method of Kufe et al. (7) for quantitative separation of RNA and 
DNA by Cs^SO^ equilibrium gradient centrifugation. After the indicated drug 
exposures to exponentially growing cultures, iced saline containing 50 pM 
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dipyridamole was added and the cell pellet was isolated by centrifugation. Cells 
were resuspended at a density of 10^ cells/ml in PBS, and 1 ml of the suspension 
was added to 2 ml of a solution containing 1.25 mg/ml pronase B (self-digested for 
15 min at 37°C), 0.01 M Tris, pH 7.4, 1 mM EDTA, and 0.5% SDS. The mixture was 
allowed to digest for 3 hours at 37°C and the total nucleic acid was isolated by 3 
cycles of phenolchloroform extraction. Nucleic acid was precipitated at -20°C 
overnight in 2 volumes of absolute ethanol in 0.4 m NaCl. The pellet isolated by 
centrifugation was resuspended in 0.5 ml of 10 nM Tris, pH 8.0, 10 mM EDTA; and 
equal volume of formamide was added and the mixture was incubated 15 min at 
80°C. To the mixture was then added 4.14 ml saturated Cs2SO^, 3.36 ml 5 mM 
EDTA; the resulting solution was then centrifuged in a Beckman 50 Tri rotor at 
40,000 rpm for at least 60 hours. The gradients were collected in about 50 
fractions of equal volume from the bottom of the tube; the trichloroacetic 
acid-precipitable material in each fraction was collected using a MASH 
multi-sample processor (Microbiological Associates, Walkersville, MD) and the 
radioactivity measured in a Packard Tricarb liquid scintillation spectrometer. 
Results 
Cytotoxicity. The cytotoxicity of 6-TG alone and in combinations with MTX was 
studied and the results are summarized in Figure 2. This graph shows the clonal 
growth of L1210 mouse leukemia cells following either a 3 hr exposure to 6-TG, a 
3 hr exposure simultaneously with 1 pM MTX and 6-TG, or a 3 hr exposure to 6-TG 
following a 3 hr pretreatment with 1 pM MTX. Treatment with 1 pM MTX alone 
for 3 hr resulted in a 52% inhibition of clonal growth compared to control, as 
depicted in Figure 2 by the horizontal dotted line. Exposure of L1210 cells to 6-TG 
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for 3 hr led to a dose-dependent inhibition of clonal growth with an LD^q of 
0.8 jjM. Pretreatment of cells for 3 hr with 1 pM MTX followed by a 3 hr 
treatment with 6-TG resulted in a synergistic inhibition of clonal growth at all 
concentrations tested; the LD^q for 6-TG was about 10 nM with 1 pM MTX 
pretreatment. In contrast, when L1210 cells were exposed simultaneously to 6-TG 
and 1 pM MTX for 3 hr, there was no enhancement of 6-TG cytotoxicity. At low 
concentrations of 6-TG (1-10 nM), the inhibition of clonal growth was at best 
additive; at higher concentrations of 6-TG (0.1-1 pM), the 1 pM MTX was actually 
antagonistic to 6-TG cytotoxicity. Thus, the modulation of 6-TG cytotoxicity can 
be either positive or negative. When 6-TG exposure follows MTX pretreatment, 
there appears to be a synergistic enhancement of 6-TG cytotoxicity, but with 
concurrent MTX and 6-TG exposure there is an apparent negative modulation or 
antagonism of 6-TG cytotoxicity. 
Cellular Uptake of 6-TG. To determine the effect of MTX pretreatment on total 
cellular uptake of 6-TG into acid-soluble intracellular pools, cells were exposed to 
1 pM (^C)6-TG either with or without pretreatment of the cells with 1 pM MTX; 
samples were removed from each culture at times ranging from 1 to 150 min, and 
the PCA-soluble radioactivity was determined as described in Methods. The 
results, normalized to the amount of ribose (as RNA) in the acid-precipitable 
fraction of each sample, are shown in Figure 3. The uptake of (^C)6-TG into 
L1210 cells is rapid, with apparent equilibration of the acid-soluble pool in less 
than five minutes; since the only earlier sampling was at one minute, no statement 
can be made comparing the relative rates of 6-TG uptake in MTX-pretreated 
versus control cells. There was a small difference in the steady-state 
concentration of 6-TG in acid-soluble intracellular pools. It is important to keep 
in mind that the acid-soluble fraction contains not only free 6-TG but all the small 
metabolites of 6-TG, including 6-TG nucleotides. MTX-pretreated cells had a 
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steady-state level of about 2.9 pmol 6-TG per pmol cellular RNA ribose, compared 
to about 2.5 pmol 6-TG per pmol cellular RNA ribose in control cells. 
Metabolism of 6-TG. As demonstrated above, MTX pretreatment resulted in 
increased uptake of 6-TG into the acid-soluble fraction. The composition of the 
acid-soluble pools was further characterized by HPLC analysis as follows. Cells 
were exposed to 0.5 pM ( C)6-TG for 60 min with and without a 3 hr pretreatment 
with 1 pM MTX. The acid-soluble fraction of the cells was isolated and anlayzed 
using HPLC as described in Methods. This allowed determination of the 
intracellular levels of free 6-TG as well as the mono-, di-, and triphosphate 
metabolites. These results are shown in Table 1. While the intracellular 
concentration of free 6-TG was almost identical in MTX-pretreated and control 
cultures, there was a substantial difference in the levels of nucleotide metabolites. 
TGMP, TGDP, and TGTP levels were all higher in MTX-pretreated cells than in 
control cells. The total 6-TG nucleotide concentration, in pmol per 10^ cells, was 
2,40 in the MTX-pretreated culture, compared to 1.55 in the control cells. MTX 
pretreatment appears to result in an enhancement of the intracellular conversion 
of 6-TG into its nucleotide derivatives. 
Incorporation of 6-TG into RNA and DNA. The effect of MTX on 6-TG 
incorporation into cellular nucleic acids was investigated. Two standard methods 
were used to quantitate the relative incorporation of 6-TG into RNA and DNA. 
The first method distinguished RNA and DNA incorporation on the basis of 
differential hydrolysis by mild alkaline and hot acid conditions. The second 
method, used to confirm the results obtained by the chemical procedure, separated 
DNA from RNA using cesium sulfate density gradients (see Methods). Figure 4 
shows the time course of incorporation of ( C)6-TG into RNA, with and without a 
3 hr pretreatment with 1 pM MTX, using the chemical method. As expected from 
the higher levels of 6-TG nucleotides measured in MTX-pretreated cells, there was 
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14 
a marked increase in the rate of ( C)6-TG incorporation into RNA when cells 
were pretreated with 1 pM MTX. The effect of MTX pretreatment on 6-TG 
incorporation into DNA was quite different. There is a dramatic suppression of 
6-TG incorporation into DNA after a 3 hr pretreatment with 1 pM MTX, as shown 
in Figure 5. 
The results obtained in experiments of similar design which used cesium 
sulfate equilibrium density gradients as the technique for separating RNA from 
DNA are shown in Figures 6 and 7. The results are qualitatively similar to those 
obtained by the differential hydrolysis procedure: MTX pretreatment at 1 pM for 
14 
1 hr leads to enhanced incorporation of ( C)6-TG into RNA while suppressing 
incorporation of (^C)6-TG into DNA. While there are quantitative differences in 
the results which are probably attributable to the inherent differences in the 
technique, there is good qualitative agreement. This lends independent support to 
the conclusions drawn using the other technique. 
Discussion 
These experiments have demonstrated that MTX can modulate the cytotoxic 
activity of 6-TG in mouse L1210 cells, and that this modulation depends on the 
schedule of drug administration. By characterizing some of the biochemical 
interactions of MTX and 6-TG in L1210 cells, these studies provide evidence for 
the metabolic basis of the drug interaction and suggest a mechanism to explain the 
synergistic cytotoxicity found under some conditions. 
Pretreatment of L1210 cells with MTX synergistically enhanced the cytotoxic 
activity of 6-TG as measured by the soft-agar cloning assay. The same MTX 
pretreatment was found to result in somewhat increased uptake of 6-TG into cells, 
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increased conversion of free 6-TG to 6-TG nucleotides, and markedly increased 
incorporation of 6-TG into RNA. Simultaneous treatment with MTX and 6-TG 
resulted in an antagnostic interaction between the drugs. An analogy can be drawn 
between these results and those already reported describing the interaction 
between MTX and 5-FU (3,4,8). The cytotoxicity of 5-FU is synergistically 
enhanced by MTX pretreatment of murine LI210, human colorectal tumor line 
HCT-8, and human breast carcinoma line 47-DN (3,8); in L1210 cells, simultaneous 
MTX and FUra treatment antagonizes the FUra cytotoxicity. It was shown (4) that 
the enhanced FUra toxicity in MTX-pretreated cells was due to increased 
intracellular levels of PRPP, the co-substrate of orotate-phosphoribosyltransferase 
which activates FUra in the cells; the increased availability of PRPP leads to 
enhanced activation of FUra to FUra-nucleotides and thus greater cytotoxicity. A 
3 hr treatment wtih 1 pM MTX, the regimen used in these experiments, was found 
to result in a 4- to 5-fold expansion of PRPP pool size; this was associated with a 
marked increase in the level of FUra-nucleotides and in the rate of FUra 
incorporation into RNA. These experiments with 6-TG are less complete in a 
number of ways, but nevertheless they demonstrate important points. The effect 
of a varying MTX dose on cytotoxicity or on the various biochemical parameters 
was not examined; we cannot say that the dose of 1 pM was optimal or that the 
pretreatment interval of 3 hr was ideal for modulation of 6-TG activity. 
Therefore, a dose-response relationship has not been established between MTX 
pretreatment (thus by inference cellular PRPP levels) and cellular 6-TG nucleotide 
levels or 6-TG incorporation into RNA. Noteworthy, however, is the recent 
report (9) of other work in this laboratory that a 3 hr exposure of L1210 cells to 
1 uM MTX increased intracellular PRPP levels from 4.1 to 125 ngm/10^ cells. This 
demonstrates a correlation between elevated PRPP levels and the increased 
activation of 6-TG, reported here, following pretreatment for 3 hrs with 1 pM 
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MTX. In the present report, 6-TG concentration was held constant in all 
experiments except the cytotoxicity assays, so the effect of varying 6-TG 
concentration or treatment interval is not known. These provisos notwithstanding, 
we have demonstrated schedule-dependent modulation of 6-TG activity by MTX 
and have provided strong evidence that the mechanism of modulation is analogous 
to that more thoroughly worked out for the MTX-FUra interaction. 
It is less clear what is the biochemical basis for 6-TG cytotoxicity. It has 
been reported (5) that the toxic effects ot 6-TG derive from its incorporation into 
cellular DNA. The results of the present study, while not conclusive, suggest that 
6-TG incorporation into RNA, rather than DNA, is the most important event 
contributing to drug toxicity. Both the selective hydrolysis and the cesium sulfate 
gradient techniques gave the result that, under conditions where MTX potentiates 
the cytotoxic effects of 6-TG, there is a marked increase in the rate of 
incorporation of 6-TG into RNA and a dramatic suppression of 6-TG incorporation 
into DNA. It is possible that incorporation of abnormal bases into RNA could cause 
alterations in RNA function. This type of effect has been observed with other 
antimetabolites such as 5-azacytidine and FUra (10,11), though the contribution of 
6-TG incorporation into RNA to cytotoxicity has not been previously established. 
While the increased 6-TG incorporation into RNA is understandable in terms of 
elevated levels of 6-TG nucleotides, the decreased incorporation of 6-TG into DNA 
is not as simple to explain. The suppression may, at least, be partly due to the 
inhibition of DNA synthesis caused by MTX; only direct measurements of the rate 
of DNA synthesis will reveal whether the differential rate of 6-TG incorporation 
into DNA is altered by MTX treatment. It is also interesting to note that 6-TGRP 
has been reported to inhibit several enzymes involved in de novo purine 
biosynthesis (2). This could provide an explanation not only for the decreased 
incorporation of 6-TG into DNA but also for a synergistic cytotoxicity with MTX 
- 13 - 

and 6-TG. The present experiments have not addressed this issue, and further work 
will be needed to clarify the relative contributions of the various effects of 6-TG 
to the ultimate lethality of the drug treatment. 
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Table 1 
Metabolism of 6-TG to 6-TG-Nucleotides 
L1210 cells both with and without pre-exposure to 1 pM MTX were exposed 
14 
to 0.5 pM ( C)6-TG for 60 min, and the cellular levels of 6-TG and 6-TG- 
nucleotides determined as described under "Materials and Methods."^ 
pmol/10^ cells Total 
Drug 6-TG TGMP TGDP TGTP Nucleotide 
6-TG 3.43 0.90 0.28 0.37 1.55 
MTX-+6-TG 3.36 1.60 0.32 0.48 2.40 
Results are representative of 4 separate experiments. The variation 
between experiments was less than ten percent. 







The effect of methotrexate (MTX) on purine synthesis and 
5-fluorouracil (5-FU) metabolism. Because of the depleted folates, 
purine synthesis ceases allowing the phosphoribosylpyrophosphate 
(PRPP), which would have been utilized for de novo purine biosynthesis, 
to be used for the conversion of 5-FU to 5-FUMP. 
Cytotoxicity of 6-TG in L1210 cells. L1210 leukemia cells were 
exposed for 3 hr to 6-TG either alone (•), simultaneously with 1 pM 
MTX (A), or following a 3 hr pre-epxosure to 1 pM MTX (o), and 
percent clone growth determined. Clonal growth of cells exposed to 
1 pM MTX alone for 3 hr is illustrated by the dotted line. Results 
represent the mean of 4 separate experiments. 
Accumulation of 6-TG in intracellular acid-soluble pools. L1210 cells 
were exposed to 1 pM (^C)6-TG for 1 to 180 minutes and the acid- 
soluble intracellular radioactivity measured. Cells were exposed either 
to 6-TG alone (•) or 6-TG following a 3 hr pretreatment with 1 pM 
MTX (o). Results are representative of 4 separate experiments. 
Incorporation of 6-TG into RNA: selective hydrolysis assay. L1210 
cells were exposed to 1 pM (^C)6-TG for 1 to 180 minutes and alkali- 
hydrolyzable, PCA-precipitable radioactivity determined (see Methods). 
Cells were exposed to 6-TG alone (•) or to 6-TG following a 3 hr 
pretreatment with 1 pM MTX (o). Results are representative of 4 
separate experiments. 
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Fig. 5 Incorporation of 6-TG into DNA: selective hydrolysis technique. LI210 
cells were exposed to 1 pM (*^C)6-TG for 1 to 180 minutes, and PCA- 
precipitable, hot acid-hydrolyzable radioactivity determined (see 
Methods). Cells were exposed to 6-TG alone (•) or to 6-TG following a 
3 hr pretreatment with 1 pM MTX (o). Results are representative of 4 
separate experiments. 
Fig. 6 Incorporation of 6-TG into RNA: cesium sulfate gradient technique. 
L1210 cells were exposed to 1 pM (^C)6-TG for 10 to 180 minutes, the 
nucleic acid isolated and separated into DNA and RNA fractions by 
cesium sulfate density gradient centrifugation, and the corresponding 
radioactivity determined (see Methods). Cells were exposed either to 
6-TG alone (•) or to 6-TG following a 3 hr pretreatment with 1 pM 
MTX (o). 
Fig. 7 Incorporation of 6-TG into DNA: cesium sulfate gradient technique. 
L1210 cells were exposed to 1 pM (^C)6-TG for 10 to 180 minutes, the 
nucleic acid isolated and separated into DNA and RNA fractions by 
cesium sulfate density gradient centrifugation, and the corresponding 
radioactivity determined (see Methods). Cells were exposed to either 
6-TG alone (#) or to 6-TG following a 3 hr pretreatment with 1 pM 
MTX (o). 
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